Scott E Martin
Overview
Explore the profile of Scott E Martin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morgan E, Saleh A, Cornelius S, Carlson S, Toni T, Cheng H, et al.
Cancer Res Commun
. 2024 Oct;
4(11):2903-2918.
PMID: 39392349
Here, RNAi library screening reveals that multiple G2/M and kinetochore components, including TTK/monopolar spindle 1, modulate TNFα-induced NF-κB activation, cell survival, and genotoxicity, underscoring their potential importance as therapeutic targets...
2.
Li D, Miermont A, Sable R, Quadri H, Mathews Griner L, Martin S, et al.
Mol Cancer Res
. 2023 Feb;
21(4):316-331.
PMID: 36790955
Implications: The CNKSR1 scaffold, identified within an RNAi screen as a novel mediator of resistance to MEK inhibition in pancreas cancer, connects the MAPK pathway and AKT signaling and may...
3.
Zimmerman Savill K, Lee B, Oeh J, Lin J, Lin E, Chung W, et al.
Nat Commun
. 2022 Apr;
13(1):2057.
PMID: 35440108
The AKT kinases have emerged as promising therapeutic targets in oncology and both allosteric and ATP-competitive AKT inhibitors have entered clinical investigation. However, long-term efficacy of such inhibitors will likely...
4.
Menendez D, Anand J, Murphy C, Bell W, Fu J, Slepushkina N, et al.
Oncotarget
. 2022 Feb;
13:332-346.
PMID: 35178190
The functional status of the tumor suppressor p53 is a critical component in determining the sensitivity of cancer cells to many chemotherapeutic agents. DNA topoisomerase II (Top2) plays essential roles...
5.
Ernst O, Sun J, Lin B, Banoth B, Dorrington M, Liang J, et al.
Sci Signal
. 2021 Aug;
14(694).
PMID: 34344832
Noncanonical inflammasome activation by cytosolic lipopolysaccharide (LPS) is a critical component of the host response to Gram-negative bacteria. Cytosolic LPS recognition in macrophages is preceded by a Toll-like receptor (TLR)...
6.
McCormack N, Abera M, Arnold E, Gibbs R, Martin S, Buehler E, et al.
Cell Rep
. 2021 May;
35(6):109125.
PMID: 33979606
Spinal muscular atrophy (SMA) is a debilitating neurological disorder marked by degeneration of spinal motor neurons and muscle atrophy. SMA results from mutations in survival motor neuron 1 (SMN1), leading...
7.
Yen I, Shanahan F, Lee J, Hong Y, Shin S, Moore A, et al.
Nature
. 2021 May;
594(7863):418-423.
PMID: 33953400
Although RAF monomer inhibitors (type I.5, BRAF(V600)) are clinically approved for the treatment of BRAF-mutant melanoma, they are ineffective in non-BRAF mutant cells. Belvarafenib is a potent and selective RAF...
8.
Shao F, Lyu X, Miao K, Xie L, Wang H, Xiao H, et al.
Adv Sci (Weinh)
. 2020 Dec;
7(23):2001914.
PMID: 33304752
Resistance to therapeutic drugs occurs in virtually all types of cancers, and the tolerance to one drug frequently becomes broad therapy resistance; however, the underlying mechanism remains elusive. Combining a...
9.
Pham T, Hagenbeek T, Lee H, Li J, Rose C, Lin E, et al.
Cancer Discov
. 2020 Nov;
11(3):778-793.
PMID: 33208393
Hippo pathway dysregulation occurs in multiple cancers through genetic and nongenetic alterations, resulting in translocation of YAP to the nucleus and activation of the TEAD family of transcription factors. Unlike...
10.
Daemen A, Cooper J, Myrta S, Wongchenko M, Lin E, Long J, et al.
Clin Cancer Res
. 2020 Oct;
27(4):1162-1173.
PMID: 33023953
Purpose: Lung adenocarcinomas comprise the largest fraction of non-small cell lung cancer, which is the leading cause of cancer-related deaths. Seventy-five percent of adenocarcinomas lack targeted therapies because of scarcity...